Alexion Pharmaceuticals

New Haven,  CT 
United States
  • Booth: 559

Alexion develops therapies for patients with devastating rare disorders and has received recent FDA approval for two innovative enzyme replacement therapies – Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). Learn more about LAL-D – a life-threatening liver disease—at booth 559.

Do you have questions about getting the most from your eBooth? Check the eBooth FAQ.